IL-32α is associated with the suppression of ICAM-1 and VCAM-1 expression on endothelial cells, resulting in attenuation of atherosclerotic lesions, with decreased leukocyte infiltration being observed following overexpression of IL-32α in the IL-32α tg Apoe−/− mouse model of atherosclerosis, suggesting that IL-32α is anti-inflammatory during atherogenesis (24). This evidence concerns the gene ICAM1 and atherosclerosis.